Microbiome biomarkers immunotherapy responsiveness: diagnostic, prognostic and therapeutic uses thereof
US11638728B2 · kind B2 · utility
0Cited by
4References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 5, 2018 |
| Grant date | May 2, 2023 |
| Priority date | — |
| Expiry date | Jun 5, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are compositions and methods comprising microbiome biomarkers of responsiveness/resistance to immunotherapy (e.g., anti-PD1/PD-L1 therapy), and diagnostic, prognostic and therapeutic uses thereof. In particular, the amount, identity, presence, and/or ratio of microflora in the microbiome of a subject is used to determine the responsiveness/resistance of the subject to immunotherapy, and/or the microbiome of a subject is manipulated to enhance the responsiveness of the subject to various immunotherapies and co-therapies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.